Prem Veera

LinkedIn post arguing that Asian clinical biology and payer frameworks differ substantially from Western markets and that oncology development should front-load Asian biomarker strategies and pricing considerations.

LinkedIn post exploring the economic challenges of CAR‑T and checkpoint inhibitor pricing in Europe, and advocating for trial designs, patient selection, and reimbursement models co-designed with health‑economic constraints.

LinkedIn post discussing the growing payer budget impact in oncology, the need to design pipeline and indication sequencing with payer thresholds in mind, and the connection between clinical strategy and market access.